Literature DB >> 2254450

Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.

P N Hawkins1, R Wootton, M B Pepys.   

Abstract

125I-Serum amyloid P component (SAP), injected intravenously into 10 normal subjects, remained predominantly intravascular with mean (SD) T1/2 (half time) in plasma of 24.5 (5.9) h. The fractional catabolic rate of 68 (19)% of the plasma pool per day was more rapid than other reported human plasma proteins. All radioactivity was excreted in the urine by 14 d. In 16 patients with monoclonal gammopathy or chronic inflammatory diseases, but without amyloidosis, 125I-SAP metabolism was normal. However, among 45 patients with biopsy-proven systemic amyloidosis (25, amyloid A type; 20, amyloid L type), 125I-SAP was cleared from the plasma more rapidly, accumulated in the amyloid deposits, and persisted there. The T1/2 in amyloid, measured directly with 131I-SAP, was 24 d. Repeat studies after 6-18 mo were notably consistent in normals but changed significantly in amyloid patients, generally correlating with clinical signs of disease progression. Measurements of 125I-SAP turnover may thus be of value for diagnosis and monitoring of amyloidosis. Analysis of SAP metabolism in amyloidosis suggests that plasma SAP is in dynamic equilibrium with a very large amyloid pool, and in two autopsies the total mass of SAP in the amyloid deposits was 2,100 and 21,000 mg, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254450      PMCID: PMC329819          DOI: 10.1172/JCI114917

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils.

Authors:  S M Breathnach; M B Pepys; H Hintner
Journal:  J Invest Dermatol       Date:  1989-01       Impact factor: 8.551

2.  Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis.

Authors:  F Coria; E Castaño; F Prelli; M Larrondo-Lillo; S van Duinen; M L Shelanski; B Frangione
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

3.  High efficiency iodination of monoclonal antibodies for radiotherapy.

Authors:  S J Mather; B G Ward
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Amyloid P component is located on elastic fibre microfibrils in normal human tissue.

Authors:  S M Breathnach; S M Melrose; B Bhogal; F C de Beer; R F Dyck; G Tennent; M M Black; M B Pepys
Journal:  Nature       Date:  1981-10-22       Impact factor: 49.962

6.  In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools.

Authors:  T H Carlson; T L Simon; A C Atencio
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

7.  Preparation of 125-I-labeled human thyroxine-binding alpha globulin and its turnover in normal and hypothyroid subjects.

Authors:  R R Cavalieri; F A McMahon; J N Castle
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

8.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Preparation of I-131-labeled human serum prealbumin and its metabolism in normal and sick patients.

Authors:  E L Socolow; K A Woeber; R H Purdy; M T Holloway; S H Ingbar
Journal:  J Clin Invest       Date:  1965-10       Impact factor: 14.808

10.  Amyloid P-component is a constituent of normal human glomerular basement membrane.

Authors:  R F Dyck; C M Lockwood; M Kershaw; N McHugh; V C Duance; M L Baltz; M B Pepys
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  24 in total

1.  Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Authors:  P N Hawkins; G A Tennent; P Woo; M B Pepys
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

Review 2.  Imaging amyloidosis with radiolabelled SAP.

Authors:  P N Hawkins; M B Pepys
Journal:  Eur J Nucl Med       Date:  1995-07

3.  Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli.

Authors:  M B Pepys; S E Booth; G A Tennent; P J Butler; D G Williams
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

5.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

6.  On the association between amyloid fibrils and glycosaminoglycans; possible interactive role of Ca2+ and amyloid P-component.

Authors:  T Stenstad; J H Magnus; K Syse; G Husby
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Authors:  M B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; W L Hutchinson; P N Hawkins; S R Nelson; J R Gallimore; J Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

8.  Studies of the structure and binding properties of hamster female protein.

Authors:  G A Tennent; M L Baltz; G D Osborn; P J Butler; G E Noble; P N Hawkins; M B Pepys
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

9.  Serologic evaluation of clinical and subclinical secondary hepatic amyloidosis in rhesus macaques (Macaca mulatta).

Authors:  Jamus G MacGuire; Kari L Christe; JoAnn L Yee; Alexis L Kalman-Bowlus; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

10.  The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.

Authors:  W L Hutchinson; G E Noble; P N Hawkins; M B Pepys
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.